Foci Pharmaceutical(SZ:002644) Zheng Quan Ri Bao·2025-04-27 09:44Core Viewpoint - Lanzhou Foci Pharmaceutical Co., Ltd. reported a revenue of 980 million yuan and a net profit of 60.07 million yuan for the year 2024, with a cash dividend of 0.12 yuan per share proposed for shareholders [2] Group 1: Financial Performance - The company achieved an operating income of 980 million yuan and a net profit attributable to shareholders of 60.07 million yuan in 2024 [2] - For Q1 2025, the company reported a revenue of 216 million yuan and a net profit of 19.38 million yuan, reflecting a year-on-year growth of 5.41% [4] Group 2: Business Operations - Foci Pharmaceutical focused on the development of traditional Chinese medicine manufacturing, completing an industrial output value of 891 million yuan and obtaining certifications from Australia TGA and Japan's Ministry of Health [3] - The company has established 1,000 acres of standardized planting bases for traditional Chinese medicinal materials and built a processing workshop capable of handling 1,000 tons of local medicinal materials [3] Group 3: Market Expansion - In 2024, the company developed 652 medical institutions and conducted 217 academic promotion events, with 10 products entering top-tier hospitals [3] - Foci Pharmaceutical expanded its online sales through partnerships with platforms like JD, Alibaba, and Meituan, and completed the construction of 6,236 standardized retail stores [3] Group 4: International Business - The company leveraged the "Belt and Road" initiative to enhance its international marketing network, achieving overseas revenue of 106 million yuan, a year-on-year increase of 23.60% [4]